Hype or hope? A review of challenges in balancing tumor control and treatment toxicity in breast cancer from the perspective of the radiation oncologist-Reference-Cited by-同舟云学术

Hype or hope? A review of challenges in balancing tumor control and treatment toxicity in breast cancer from the perspective of the radiation oncologist

Published:2023-07-28 Issue: Volume: Page:
ISSN:1699-3055
Container-title:Clinical and Translational Oncology
language:en
Short-container-title:Clin Transl Oncol

Author:

González-Viguera Javier^ORCID,Martínez-Pérez Evelyn,Pérez-Montero Héctor,Arangüena Marina,Guedea Ferran,Gutiérrez-Miguélez Cristina

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12094-023-03287-2.pdf

Reference97 articles.

1. Hong R, Xu B. Breast cancer: an up-to-date review and future perspectives. Cancer Commun (Lond). 2022;42(10):913–36. https://doi.org/10.1002/cac2.12358.

2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG); Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death. meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378(9804):1707–16. https://doi.org/10.1016/S0140-6736(11)61629-2.

3. EBCTCG (Early Breast Cancer Trialists' Collaborative Group); McGale P, Taylor C, Correa C, Cutter D, Duane F, Ewertz M, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality. meta-analysis of individual patient data for 8135 women in 22 randomised trials [published correction appears in Lancet. 2014 Nov 22;384(9957):1848]. Lancet. 2014;383(9935):2127–35. https://doi.org/10.1016/S0140-6736(14)60488-8.

4. Haviland JS, Owen JR, Dewar JA, Agrawal RK, Barrett J, Barrett-Lee PJ, et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer. 10-year follow-up results of two randomised controlled trials. Lancet Oncol. 2013;14(11):1086–94. https://doi.org/10.1016/S1470-2045(13)70386-3.

5. Offersen BV, Alsner J, Nielsen HM, Jakobsen E, Nielsen M, Krause M, et al. Hypofractionated versus standard fractionated radiotherapy in patients with early breast cancer or ductal carcinoma in situ in a randomized phase III trial: the DBCG HYPO trial. J Clin Oncol. 2020;38(31):3615–25. https://doi.org/10.1200/JCO.20.01363.